These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 34644203)

  • 21. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
    Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
    Front Neurol; 2021; 12():788159. PubMed ID: 35069416
    [No Abstract]   [Full Text] [Related]  

  • 22. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers.
    Shibata M; Fujita K; Hoshino E; Minami K; Koizumi K; Okada S; Sakai F
    BMC Neurol; 2024 Jan; 24(1):32. PubMed ID: 38238659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study.
    de Vries Lentsch S; Verhagen IE; van den Hoek TC; MaassenVanDenBrink A; Terwindt GM
    Eur J Neurol; 2021 Dec; 28(12):4194-4203. PubMed ID: 34424593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.
    Raffaelli B; Terhart M; Overeem LH; Mecklenburg J; Neeb L; Steinicke M; Reuter U
    Cephalalgia; 2022 Apr; 42(4-5):326-334. PubMed ID: 34579559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study.
    Straube A; Broessner G; Gaul C; Hamann X; Hipp J; Kraya T; Neeb L
    J Headache Pain; 2023 May; 24(1):59. PubMed ID: 37221478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
    Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience.
    Raffaelli B; Fitzek M; Overeem LH; Storch E; Terhart M; Reuter U
    J Headache Pain; 2023 Feb; 24(1):16. PubMed ID: 36843007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
    Charleston L; Talon B; Sullivan C; Anderson C; Kymes S; Regnier SA; Soni-Brahmbhatt S; Nahas SJ
    J Headache Pain; 2023 Aug; 24(1):101. PubMed ID: 37532991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.
    Iannone LF; Fattori D; Marangoni M; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2023 Feb; 37(2):189-202. PubMed ID: 36656298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.
    Muñoz-Vendrell A; Campoy S; Caronna E; Alpuente A; Torres-Ferrus M; Nieves Castellanos C; Olivier M; Campdelacreu J; Prat J; Camiña Muñiz J; Molina Martínez FJ; Mínguez-Olaondo A; Ruibal Salgado M; Santos Lasaosa S; Navarro Pérez MP; Morollón N; López Bravo A; Cano Sánchez LM; García-Sánchez SM; García-Ull J; Rubio-Flores L; Gonzalez-Martinez A; Quintas S; Echavarría Íñiguez A; Gil Luque S; Castro-Sánchez MV; Adell Ortega V; García Alhama J; Berrocal-Izquierdo N; Belvís R; Díaz-Insa S; Pozo-Rosich P; Huerta-Villanueva M
    J Headache Pain; 2023 Jun; 24(1):63. PubMed ID: 37268904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
    Schenk H; Holle D; Nsaka M; Kleinschnitz C; Glas M; Scheffler A
    J Headache Pain; 2022 May; 23(1):55. PubMed ID: 35538414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany.
    Scheffler A; Wenzel P; Bendig M; Gendolla A; Basten J; Kleinschnitz C; Nsaka M; Lindner D; Naegel S; Burow P; Fleischmann R; Holle D
    J Headache Pain; 2024 May; 25(1):79. PubMed ID: 38755541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
    Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
    J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
    Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
    J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study.
    Varnado OJ; Brady BL; Zagar AJ; Robles YP; Hoyt M
    Patient Prefer Adherence; 2024; 18():69-88. PubMed ID: 38223442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
    Curone M; Tullo V; Didier HA; Bussone G
    Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.